SEARCH

SEARCH BY CITATION

References

  • 1
    Tchaikovski SN, Rosing J. Mechanisms of estrogen-induced venous thromboembolism. Thromb Res 2010;126:511.
  • 2
    Tanis BC, van den Bosch MA, Kemmeren JM, Cats VM, Helmerhorst FM, Algra A, et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med 2001;345:178793.
  • 3
    Vandenbroucke JP, Rosing J, Bloemenkamp KW, Middeldrop S, Helmerhorst FM, Bouma BM, et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001;344:152735.
  • 4
    Petitti DB. Combination estrogen-progestin oral contraceptives. N Engl J Med 2003;349:144350.
  • 5
    Orti G, Mira Y, Vaya A. Acute myocardial infarction associated with Yasmin oral contraceptive. Clin Appl Thromb Hemost 2007;13:3367.
  • 6
    Mishell DR Jr. YAZ and the novel progestin drospirenone. J Reprod Med 2008;53:7218.
  • 7
    Parkin L, Sharples K, Hernandez RK, Jick SS. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database. Br Med J 2011;342:d1239.
  • 8
    Jick SS, Hernandez RK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. Br Med J 2011;342:d2151.
  • 9
    Dinger J, Assmann A, Mohner S, Minh TD. Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study. J Fam Plann Reprod Health Care 2010;36:1239.
  • 10
    FDA Advisory Committee Joint Meeting: Reproductive Health Drugs; Drug Safety and Risk Management. 2011 [www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM284784.pdf]. Accessed 12 January 2012.
  • 11
    FDA Drug Safety Communication: Updated information about the FDA-funded study on risk of blood clots in women taking birth control pills containing drospirenone. 2011[www.fda.gov/Drugs/DrugSafety/ucm299305.htm]. Accessed 30 December 2011.
  • 12
    Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. J Am Med Assoc 2000;283:200812.
  • 13
    Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151:W64.
  • 14
    Van Grootheest K, Vrieling T. Drug points: thromboembolism associated with the new contraceptive Yasmin. Br Med J 2003;326:257.
  • 15
    Lopez M, Vaya A, Martinez Triguero ML, Contreras MT, Todolí J, Ricart A, et al. Yasmin and venous thromboembolism: new case reports. Clin Hemorheol Microcirc 2009;42:659.
  • 16
    Oo TH. Deep vein thrombosis associated with the new oral contraceptive Yasmin. South Med J 2009;102:9856.
  • 17
    Pearce HM, Layton D, Wilton LV, Shakir SAW. Deep vein thrombosis and pulmonary embolism reported in the Prescription Event Monitoring Study of Yasmin. Br J Clin Pharmacol 2005;60:98102.
  • 18
    Marti Gil C, Mulet Alberola A, Mejia Recuero M, Barreira Hernandez D, Llopis Salvia P, Barreda Hernandez D. Update on combined oral contraceptives: risk of venous thromboembolism. Drospirenone versus other progestins. Eur J Hosp Pharm 2012;19:254.
  • 19
    Cabou C, Lacroix I, Roncalli J, Elbaz M, Caillaux D, Damase-Michel C, et al. Myocardial infarction in a young female smoker taking oral contraception. Infarctus du myocarde chez une jeune femme fumeuse sous contraception orale. Arch Mal Coeur Vaiss 2006;99:805.
  • 20
    Zehir R, Karabay CY, Kocabay G. Myocardial infarction and spontaneous dissection of coronary artery due to oral contraceptive. J Cardiovasc Med 2011;12:44850.
  • 21
    Vaya A, Mira Y, Ferrando F, Aznar J, Garcia-Fuster Ma J. Transient ischaemic attack associated with the new contraceptive Yasmin. Thromb Res 2004;112:121.
  • 22
    Lidegaard O, Nielsen LH, Skovlund CW, Skjeldestad FE, Lokkegaard E. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001–9. Br Med J 2011;343:d6423.
  • 23
    Gronich N, Lavi I, Rennert G. Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based cohort study. Can Med Assoc J 2011;183:E131925.
  • 24
    Dinger JC, Heinemann LA, Kuhl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception 2007;75:34454.
  • 25
    Lidegaard O, Lokkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. Br Med J 2009;339:b2890.
  • 26
    Seeger JD, Loughlin J, Eng PM, Clifford CR, Cutone J, Walker AM. Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives. Obstet Gynecol 2007;110:58793.
  • 27
    Leppee M, Culig J. Difference between drospirenone-containing oral contraceptives and other oral contraceptives related to risk of venous thromboembolism. J Fam Plann Reprod Health Care 2012;38:1378.
  • 28
    Vlieg AV, Helmerhorst FM, Vandenbroucke JP, Doggen CJM, Rosendaal FR. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. Br Med J 2009;339:b2921.
  • 29
    Lidegaard O, Lokkegaard E, Jensen A, Skovlund CW, Keiding N. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med 2012;366:225766.
  • 30
    Suissa S. The Transnational study of oral contraceptive cardiovascular safety: history and science. J Clin Epidemiol 2009;62:58893.
  • 31
    Suissa S, Blais L, Spitzer WO, Cusson J, Lewis M, Heinemann L. First-time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception 1997;56:1416.
  • 32
    Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003;158:91520.
  • 33
    Sorensen HT, Horvath-Puho E, Pedersen L, Baron JA, Prandoni P. Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. Lancet 2007;370:17739.
  • 34
    Yasmin: risk of venous thromboembolism higher than levonorgestrel-containing pills. 2011 [www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON120214]. Accessed 30 December 2011.
  • 35
    Yasmin and Yaz (drospirenone): Updated information on increased risk of blood clots. 2011 [www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/_2011/2011_164-eng.php]. Accessed 30 December 2011.
  • 36
    FDA Drug Safety Communication: Updated information about the risk of blood clots in women taking birth control pills containing drospirenone. 2012 [www.fda.gov/Drugs/DrugSafety/ucm299305.htm]. Accessed 14 May 2012.
  • 37
    Manzoli L, De Vito C, Marzuillo C, Boccia A, Villari P. Oral contraceptives and venous thromboembolism: a systematic review and meta-analysis. Drug Saf 2012;35:191205.
  • 38
    Martinez F, Ramirez I, Perez-Campos E, Latorre K, Lete I. Venous and pulmonary thromboembolism and combined hormonal contraceptives. Systematic review and meta-analysis. Eur J Contracept Reprod Health Care 2012;17:729.
  • 39
    Lidegaard O. The influence of thrombotic risk factors when oral contraceptives are prescribed. A control-only study. Acta Obstet Gynecol Scand 1997;76:25260.
  • 40
    Heinemann LA, Dinger J. Safety of a new oral contraceptive containing drospirenone. Drug Saf 2004;27:100118.
  • 41
    Dinger J, Shapiro S. Combined oral contraceptives, venous thromboembolism, and the problem of interpreting large but incomplete datasets. J Fam Plann Reprod Health Care 2012;38:26.